Biotechnology

DIGITAL THERAPEUTICS STARTUP RESPIREE™ GAINS US FDA CLEARANCE FOR ITS RS001 CARDIO-RESPIRATORY WEARABLE

SINGAPORE, March 9, 2023 /PRNewswire/ -- Digital therapeutics startup Respiree  has received the United States Food and Drug Administration's 510(k) clearance for its RS001 cardio-respiratory wearable. Illustrative Ima...

2023-03-09 08:14 6204

Mallinckrodt Announces Reimbursement Approval in Japan for the CELLEX® Extracorporeal Photopheresis (ECP) System for the Treatment of Chronic Graft Versus Host Disease (cGvHD)

– CELLEX ECP is now available for reimbursement in Japan for patients who are steroid-resistant or -intolerant and suffering from cGvHD – DUBLIN, March 9, 2023 /PRNewswire/ -- Mallinckrodt plc, (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, tod...

2023-03-09 05:00 2206

Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU

MELBOURNE, Australia, March 9, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations from the Company's carbonic anhydrase IX (CAIX) targeting kidney and bladder cancer programs at the 38th Annual European Association of Urology (EAU) Cong...

2023-03-09 04:51 2389

BIORCHESTRA Participating in Two Upcoming Therapeutic RNA-Focused Events

CAMBRIDGE, Mass. and DAEJEON, South Korea, March 8, 2023 /PRNewswire/ -- BIORCHESTRA , a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS) by leveraging its proprietary Brain-Targeting RNAi Nanomedi...

2023-03-08 22:47 1871

Hovione receives the 2023 CDMO Leadership Award in all six categories and is Champion in Compatibility and Expertise

LISBON, Portugal, March 8, 2023 /PRNewswire/ -- Hovione, the leader in spray drying and particle engineering, won the2023 CDMO Leadership Award across all six categories – capability, compatibility, expertise, quality, reliability and service across all thre...

2023-03-08 22:00 2013

JW Therapeutics Announces Initiation of Clinical Study of Carteyva® in First-line Treatment in Patients with High-Risk Large B-Cell Lymphoma

SHANGHAI, March 8, 2023  /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the initiation of clinical study of Carteyva® (relmacabtagene autoleucel inje...

2023-03-08 17:30 3167

ICP DAS - BMP to show KIMES 2023 visitors high-performance medical TPU pellets in Seoul, Korea

HSINCHU, March 7, 2023 /PRNewswire/ -- ICP DAS - BMP (Biomedical Polymers), a Taiwan medical TPU (thermoplastic polyurethane) supplier, will have its first showcase in KIMES 2023, Korea. Exhibit highlights include TPU pellets with radiopacifiers of 50% tungsten (W50) and 40% Barium Sulfate (B40),...

2023-03-08 14:00 2727

ONEDAY BIOTECH to unveil 'One Drilling System' at IDS 2023

* One Drilling System Completing the Implant Procedure with Just One Drilling Exclusively * Company Specializing in Implants Pursuing 'One-Day-Completion Implant' SEOUL, South Korea, March 8, 2023 /PRNewswire/ -- ONEDAY BIOTECH (CEO Kim Jin -hwan), a dental product manufacturer specializing in...

2023-03-08 07:00 3292

MSCI ESG Updated I-Mab to "A" Rating

GAITHERSBURG, MD. and SHANGHAI, March 7, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that I-Mab has been granted "A" rating by MSCI (Morgan ...

2023-03-07 21:02 1842

AnPac Bio Announces Receipt of the First Payment from a Malaysia Customer On a Signed US$1.5 Million Cancer Detection Equipment Purchase Contract

NEW YORK, March 7, 2023 /PRNewswire/ – AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio" or the "Company" (Nasdaq: ANPC), a company with operations inthe United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commer...

2023-03-07 20:30 1575

Medlab Asia and Asia Health returns to Thailand after securing deals worth US$35m in 2022

BANGKOK, March 7, 2023 /PRNewswire/ -- Informa Markets and IMPACT Exhibition Management Co.,Ltd. have confirmed that Medlab Asia and Asia Health, a major healthcare event, will return toThailand following the success of the 2022 edition, after shining a spotlight on the growth of healthcare and l...

2023-03-07 16:49 2405

GenScript ProBio Congratulates Eutilex's IND Clearance from MFDS

NANJING, China, March 7, 2023 /PRNewswire/ -- Recently, Eutilex, a partner of GenScript ProBio, announced MFDS(Ministry of Food and Drug Safety) clearance of its hepatocellular carcinoma clinical trial application for innovative CAR-T program (EU307). GenScript ProBio extends congratulations o...

2023-03-07 10:00 2299

AnPac Bio-Medical Science Announces US$5 Million Private Placement

NEW YORK, March 6, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) ("AnPac Bio," the "Company" or "we"), a company with operations inthe United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business ...

2023-03-06 21:30 3397

Hummingbird Bioscience Exercises Its Option to License the Clinical Trial Results from Cancer Research UK to Support Further Development of HMBD-001

SINGAPORE and LONDON, March 6, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, and Cancer Research Horizons, the innovation arm of Cancer Research UK (CRUK), today...

2023-03-06 21:00 2181

HanAll Biopharma's Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclimab in Myasthenia Gravis

* The trial met its primary endpoint and key secondary endpoints, with a favorable safety profile * Batoclimab is one of the most advanced FcRn inhibitors being developed in Greater China for the treatment of myasthenia gravis SEOUL, South Korea, March 6, 2023 /PRNewswire/ -- HanAll Biopharma...

2023-03-06 20:00 1669

Results of CLDN18.2-targeting Immuno-PET Probe for Non-invasive Imaging in Gastrointestinal Tumors Published

SUZHOU, China, March 3, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announces that the study ...

2023-03-03 14:56 2832

Porton Advanced Collaborates with DanausGT to Accelerate the Development of Gene and Cell Therapy

SUZHOU,China, March 2, 2023 /PRNewswire/ -- Porton Advanced Solutions Ltd. (Porton Advanced) and DanausGT Biotechnology Co., Ltd. (DanausGT) announced on February 27, 2023, a strategic collaboration in gene and cell therapy pipelines to expedite the development of innovative therapeutics.

2023-03-02 20:00 2148

Abbisko Therapeutics Announces an Out-License Agreement with Allist for ABK3376

SHANG HAI, March 2, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that it has entered into an exclusive Out-License Agreement (the "Agreement" hereafter) with Shanghai Allist Pharmaceuticals Co., Ltd., ("Allist" hereafter) for the further ...

2023-03-02 19:15 3392

Sanyou Biopharmaceuticals opens Cambridge MA, US office, expanding its business outreach to a central hub of biotech network

CAMBRIDGE, Mass., March 2, 2023 /PRNewswire/ -- Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is opening a new office in Cambridge Innovation Centre, CIC, marking a new era towards the company's rising ambition on serving and collaborating with world's best biotech sta...

2023-03-02 18:00 1713

ExoCoBio obtained 2 GMP Licenses for Exosome Biopharmaceuticals from Korea MFDS and for Hyaluronic Acid (HA) Dermal Fillers from Brazil ANVISA

* ExoGMP™ is the world's largest exosome manufacturing facility in Osong, South Korea. * Cellosome™ HA fillers are expected to be approved in 2023. * ExoCoBio has all 3 types of GMP clearance for pharmaceuticals, medical devices, & cosmetics. SEOUL, South Korea, March 2, 2023 /PRNewswire/ -...

2023-03-02 14:09 4000
1 ... 121122123124125126127 ... 307